BRVE$21.511.51%0.32
Braveheart Bio, Inc. Common Stock (BRVE)
Date: 2026-10-30 16:00O: 21.29H: 21.77L: 20.75C: 21.51Vol: 533.7k
Braveheart Bio, Inc. Common Stock stock is traded at $21.51, with a volume of 533,667. It is up +1.51% in the last 24 hours and up +6.49% over the past month.
Previous Close:
$21.19
Open:
$21.29
24h Volume:
533,667
Relative Volume:
2.14
Market Cap:
$1.94B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.33%
1M Performance:
+6.49%
6M Performance:
0.00%
1Y Performance:
0.00%
1-Day Range:
$0.00$0.00
1-Week Range:
$20.62$22.22
52-Week Range:
$17.86$32.00
Braveheart Bio, Inc. Common Stock Stock (BRVE) Company Profile
Compare BRVE vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRVE Braveheart Bio, Inc. Common Stock | $21.51 | $1.94B | $0 | $0 | $0 | $0.00 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Braveheart Bio, Inc. Common Stock Stock (BRVE) Upgrades & Downgrades
Braveheart Bio, Inc. Common Stock Stock (BRVE) Financials Data
There is no financial data for Braveheart Bio, Inc. Common Stock (BRVE). Check out other stocks for more information.
Revenue
Chart is being upgraded
This chart will be back soon.
Net Income
Chart is being upgraded
This chart will be back soon.
Cash Flow
Chart is being upgraded
This chart will be back soon.
EPS
Chart is being upgraded
This chart will be back soon.
Braveheart Bio, Inc. Common Stock Stock (BRVE) Insider Trading
- Chimovits ErezAug 07 '26Director
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 1,940,000
- Value ($)
- 34,920,000
- #Shares Total
- 11,901,826
- ORBIMED ADVISORS LLCAug 07 '26Director
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 1,940,000
- Value ($)
- 34,920,000
- #Shares Total
- 11,901,826
- Forbion Growth Opportunities FAug 07 '2610% Owner
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 1,920,000
- Value ($)
- 34,560,000
- #Shares Total
- 11,640,546
- Forbion Growth Opportunities FAug 07 '2610% Owner
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 1,680,000
- Value ($)
- 30,240,000
- #Shares Total
- 10,185,478
- Rickey James PaulAug 07 '26Chief Financial Officer
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 27,777
- Value ($)
- 499,986
- #Shares Total
- 520,927
- Viehbacher ChristopherAug 07 '26Director
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 83,333
- Value ($)
- 1,499,994
- #Shares Total
- 609,519
- Malek David IAug 07 '26Director
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 4,166
- Value ($)
- 74,988
- #Shares Total
- 533,845
- Anderson Michele A.Aug 07 '26Chief Development Officer
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 1,111
- Value ($)
- 19,998
- #Shares Total
- 332,161
- Murdoch TravisAug 07 '26CEO and President
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 83,333
- Value ($)
- 1,499,994
- #Shares Total
- 2,940,670
- Lubner David CharlesAug 07 '26Director
- Transaction
- Buy
- Cost
- $18.00
- #Shares
- 55,555
- Value ($)
- 999,990
- #Shares Total
- 55,555
